[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483711":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":41,"responsibleParty":58,"collaborators":35,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":35,"enrollmentInfo":71,"targetDuration":35,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":35,"overallStatus":43,"whyStopped":35,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Oslo University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental vs Control","EXPERIMENTAL","The patients who are randomized to receive meropenem 1 gram 6 times daily in 15 minutes infusions.",[13],"Drug: Meropenem 1000 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Controls","ACTIVE_COMPARATOR","The patients who are randomized to receive meropenem 2 gram 3 times daily in 3 hours infusions.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Meropenem 1000 mg","given as 6 or 3 infusions in 15 minues or 3 hours.",[15,9],[26],"Meropenem 2000 mg",[28],{"name":29,"affiliation":5,"role":30},"Ingvild Nordøy, PhD","PRINCIPAL_INVESTIGATOR",[32,37],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","+4793028084",null,"inordoy@ous-hf.no",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Trine Kåsine, PhD","+4790779669","trikaa@ous-hf.no",[42],{"facility":5,"status":43,"city":44,"state":35,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Oslo","0242","Norway","NO",{"type":49,"coordinates":50},"Point",[51,52],10.74609,59.91273,{"lat":52,"lon":51},[55,56],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},{"name":38,"role":33,"phone":39,"phoneExt":35,"email":57},"trikka@ous-hf.no",{"type":30,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"Ingvild Nordøy","Senior consultant, MD, PhD","100483711","a-pilot-study-for-optimizing-meropenem-administration-in-the-icu-100483711",false,"NCT05578586","A Pilot Study for Optimizing Meropenem Administration in the ICU","A Pilot Study for Optimizing Meropenem Administration in the Intensive Care Unit - Short Six Times vs Prolonged Three Times Courses Daily","MER6","Inclusion Criteria:\n\n1. Patients ≥ 18 years admitted to the ICU at Oslo University Hospital, Rikshospitalet and\n2. who shall be treated with meropenem because of proven or suspected serious infection and\n3. who give their written informed consent either directly or through next of kin\n\nExclusion Criteria: Patients\n\n1. with known hypersensistivity to betalactam antibiotics or\n2. who use of valproat or\n3. who are pregnant or\n4. the lack of consent.","ALL","18 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"NA","Can antibiotic drugs be administered faster and make acceptable serum concentrations if we give short but multiple infusions compared to long and fewer infusions? In this study we will compare giving meropenem 1 gram 6 times daily in 15 minutes infusions to the recommended 2 gram 3 times daily in 3 hours infusions. In patients in the intensive care unit, the need for intravenous access is of essence. If 6 short infusions results in the same serum concentrations as 3 long infusions, we will increase intravenous access from 15 to 22.5 hours daily.",[79],"Drug Effect","2025-04-23",{"date":82,"type":83},"2025-04-24","ACTUAL",{"date":85,"type":83},"2021-12-14",{"date":87,"type":73},"2027-06",{"name":5,"class":6},1]